STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Professor Paul Workman to its Board.

Read the press release

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 2022 Dates To be Confirmed